Achondroplasia Therapeutics Pipeline is Witnessing Significant Growth due to Positive Clinical Results | Top players are BioMarin Pharmaceutical Inc., Ascendis Pharma A/S, Therachon
Achondroplasia is a common disorder of dwarfism with disproportionate stature. It is an autosomal dominant disorder that occurs due to mutation in fibroblast growth factor receptor 3 (FGFR3) gene, which is located on short arm of chromosome 4. The disorder is characterized by macrocephaly, shortened-limbs (rhizomelic dwarfism), midface retrusion, and frontal bossing. The achondroplasia therapeutics pipeline study covers seven active drug candidates in different stages of development.
Download the sample report @ https://www.pharmaproff.com/request-sample/1153
Achondroplasia therapeutics pipeline has majority of candidates in the Pre-Clinical stage of development. A peptide-based drug candidate namely, vosoritide, is in the Phase III stage of development by BioMarin Pharmaceutical Inc., for the treatment of achondroplasia.
Get the detailed analysis @ https://www.pharmaproff.com/report/achondroplasia-therapeutics-pipeline-analysis
According to the research findings, majority of the drug candidates for the treatment of achondroplasia are being developed to be administered by the subcutaneous route. Some of the key advantages of subcutaneous route are sustained release of drug, improved patient condition, lower risk of systemic infections, less painful administration, and less-expensive nature of the administered drugs.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1153
It has been observed that many pharmaceutical companies are adopting advanced technologies for the development of achondroplasia therapeutics. These technologies are helpful in the development of drugs as either combination therapies or single-agent therapies. For instance, RIBOMIC Inc.’s, RiboART system, is the essential element in drug discovery technology, that helps in the discovery of various new drugs for the treatment of the various diseases including achondroplasia.
Some of the key players involved in the development of achondroplasia therapeutics include BioMarin Pharmaceutical Inc., Ascendis Pharma A/S, and Therachon AG.
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Toll-free: +1-888-778-7886 (USA/Canada)
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Achondroplasia Therapeutics Pipeline is Witnessing Significant Growth due to Positive Clinical Results | Top players are BioMarin Pharmaceutical Inc., Ascendis Pharma A/S, Therachon here
News-ID: 1674883 • Views: 1112
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances
More Releases for Achondroplasia
Achondroplasia Market Insight, Epidemiology and Market Forecast - 2027
Achondroplasia Market research report is the new statistical data source added by Infinity Business Insights. Achondroplasia is a genetic disease characterised by dwarfism as its major symptom. The limbs and legs of people who have the disease are short, but the torso is usually average length. Males have an average adult height of 131 centimetres (4 ft 4 in) while girls have an average adult height of 123 centimetres (4
2020 Prediction for Achondroplasia Treatment market: Key Players and Driving Fac …
Prophecy Market Insights recently presented Achondroplasia Treatment market report which provides reliable and sincere insights related to the various segments and sub-segments of the market. The market study throws light on the various factors that are projected to impact the overall dynamics of the Achondroplasia Treatment market over the forecast period (2019-2029). The Achondroplasia Treatment research study contains 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and
Global Achondroplasia Treatment Market Data Survey Report 2025
In 2017, the Global Achondroplasia Treatment Market showcase estimate was million US$ and is conjecture to million US in 2025, developing at a CAGR of from 2018. The targets of this investigation are to characterize, fragment, and task the measure of the Achondroplasia Treatment showcase dependent on organization, item type, application and key locales. Global Achondroplasia Treatment Market report examines the worldwide market size of Achondroplasia Treatment in key areas
Achondroplasia Pharmaceutical and Healthcare Pipeline Review H1
Summary Achondroplasia is a bone growth disorder that causes disproportionate dwarfism. This is caused by mutations in the FGFR3 gene. Symptoms include decreased muscle tone, apnea, hydrocephalus, short arms and legs, disproportionately large head compared to the body and kyphosis. Treatment includes growth hormones. GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/3066566-achondroplasia-pipeline-review-h1-2018 Report Highlights Pharmaceutical and Healthcare latest pipeline guide Achondroplasia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Achondroplasia
Achondroplasia Treatment Industry – Treatment Analysis,Research,Review to 2025
WiseGuyReports.Com Publish a New Market Research Report On –“ Achondroplasia Treatment Industry – Treatment Analysis,Research,Review to 2025”. Description: In this report, the global Achondroplasia Treatment market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market
Achondroplasia Pipeline Insight and Therapeutic Assessment Reviewed in 2017
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide “Achondroplasia - Pipeline Review, H2 2017”, provides an overview of the Achondroplasia (Musculoskeletal Disorders) pipeline landscape. Request For Free Sample - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1324481 Achondroplasia is a bone growth disorder that causes disproportionate dwarfism. This is caused by mutations in the FGFR3 gene. Symptoms include decreased muscle tone, apnea, hydrocephalus, short arms and legs, disproportionately large head compared to the body and kyphosis.